Suppr超能文献

相似文献

1
Potent D-peptide inhibitors of HIV-1 entry.
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):16828-33. doi: 10.1073/pnas.0708109104. Epub 2007 Oct 17.
2
Characterization of resistance to a potent D-peptide HIV entry inhibitor.
Retrovirology. 2019 Oct 22;16(1):28. doi: 10.1186/s12977-019-0489-7.
3
Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry.
Bioconjug Chem. 2012 Jun 20;23(6):1252-8. doi: 10.1021/bc300076f. Epub 2012 May 17.
5
Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.
Cell. 1999 Oct 1;99(1):103-15. doi: 10.1016/s0092-8674(00)80066-5.
6
Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92. doi: 10.1073/pnas.201392898.
8
Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance.
J Virol. 2010 Nov;84(21):11235-44. doi: 10.1128/JVI.01339-10. Epub 2010 Aug 18.
9
Structural and Thermodynamic Analysis of HIV-1 Fusion Inhibition Using Small gp41 Mimetic Proteins.
J Mol Biol. 2019 Aug 9;431(17):3091-3106. doi: 10.1016/j.jmb.2019.06.022. Epub 2019 Jun 27.
10
Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity.
J Biol Chem. 2001 Aug 3;276(31):29485-9. doi: 10.1074/jbc.C100317200. Epub 2001 Jun 19.

引用本文的文献

1
De novo design of D-peptide ligands: Application to influenza virus hemagglutinin.
Proc Natl Acad Sci U S A. 2025 Jul;122(26):e2426554122. doi: 10.1073/pnas.2426554122. Epub 2025 Jun 27.
2
Functional Ambidexterity of an Ancient Nucleic Acid-Binding Domain.
Angew Chem Int Ed Engl. 2025 Jun 17;64(25):e202505188. doi: 10.1002/anie.202505188. Epub 2025 May 8.
3
Generating a mirror-image monobody targeting MCP-1 via TRAP display and chemical protein synthesis.
Nat Commun. 2024 Dec 23;15(1):10723. doi: 10.1038/s41467-024-54902-x.
4
Accurate de novo design of heterochiral protein-protein interactions.
Cell Res. 2024 Dec;34(12):846-858. doi: 10.1038/s41422-024-01014-2. Epub 2024 Aug 14.
5
Analysis, Modeling, and Target-Specific Predictions of Linear Peptides Inhibiting Virus Entry.
ACS Omega. 2023 Nov 22;8(48):46218-46226. doi: 10.1021/acsomega.3c07521. eCollection 2023 Dec 5.
6
Sequence-based prediction of the intrinsic solubility of peptides containing non-natural amino acids.
Nat Commun. 2023 Nov 17;14(1):7475. doi: 10.1038/s41467-023-42940-w.
7
Rational design of the genetic code expansion toolkit for encoding of D-amino acids.
Front Genet. 2023 Oct 13;14:1277489. doi: 10.3389/fgene.2023.1277489. eCollection 2023.
8
Two-Chamber Aminocarbonylation of Aryl Bromides and Triflates Using Amino Acids as Nucleophiles.
J Org Chem. 2023 Sep 15;88(18):12978-12985. doi: 10.1021/acs.joc.3c00972. Epub 2023 Aug 28.
9
Synthesis and applications of mirror-image proteins.
Nat Rev Chem. 2023 Jun;7(6):383-404. doi: 10.1038/s41570-023-00493-y. Epub 2023 May 12.
10
Computational Protein Design for COVID-19 Research and Emerging Therapeutics.
ACS Cent Sci. 2023 Mar 20;9(4):602-613. doi: 10.1021/acscentsci.2c01513. eCollection 2023 Apr 26.

本文引用的文献

1
Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion.
Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):13938-43. doi: 10.1073/pnas.0601036103. Epub 2006 Sep 8.
2
Kinetic dependence to HIV-1 entry inhibition.
J Biol Chem. 2006 Sep 1;281(35):25813-21. doi: 10.1074/jbc.M601457200. Epub 2006 Jun 27.
3
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.
Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14759-64. doi: 10.1073/pnas.0506927102. Epub 2005 Oct 3.
4
Inhibiting HIV fusion with a beta-peptide foldamer.
J Am Chem Soc. 2005 Sep 28;127(38):13126-7. doi: 10.1021/ja053444+.
5
Steric accessibility of the HIV-1 gp41 N-trimer region.
J Biol Chem. 2005 Apr 1;280(13):12567-72. doi: 10.1074/jbc.M412770200. Epub 2005 Jan 18.
8
HIV-1 gp41 as a target for viral entry inhibition.
Curr Pharm Des. 2004;10(15):1805-25. doi: 10.2174/1381612043384448.
9
Effect of pegylation on pharmaceuticals.
Nat Rev Drug Discov. 2003 Mar;2(3):214-21. doi: 10.1038/nrd1033.
10
Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion.
Angew Chem Int Ed Engl. 2002 Jan 18;41(2):278-81. doi: 10.1002/1521-3773(20020118)41:2<278::aid-anie278>3.0.co;2-a.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验